Skip to main content

Cookies

This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use. Please read our cookie policy for more information on the use of cookies on this website.

Top
  • COVID-19
    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
  • Products
    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers
Home

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers

Main Navigation

  • COVID-19
    Vaccine Development
    Vaccine Development

    Accelerating global operations to manage and process samples critical to vaccine development.

    Azenta Life Sciences Virtual Booth
    Azenta Life Sciences Virtual Booth

    The exhibition experience to your desktop or mobile device

    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
    Resources Center

    Learn about sample management best practices, gain advice from industry leaders, gain access to global regulatory and logistics guidelines and find simple support tools that can help you make better sample management decisions.

    Resources Center
  • Products
    Azenta Sample Pack and Catalog
    Sample Tube Pack Request

    Improve sample tracking, ensure sample integrity and drive process efficiency with Azenta Sample Storage Tubes. Explore the range, and select the best tube for your workflow.

    Low DNA Binding Microplates
    Low Binding Microplates

    Ultra low DNA binding microplates made from PP, fit for Next Generation Sequencing (NGS) and other sensitive applications with ultra-low DNA input. Off the shelf options. Custom solutions on request.

    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    Clinical Trial Management
    Clinical Trial Management

    Life science organizations must collect and manage large numbers of research samples to bring a new therapeutic or diagnostic to market. This is a complex process.

    Sample Preparation & Lab Analytical Services
    Genomics Services by GENEWIZ

    Comprehensive genomics services provide end to end solutions and best-in-class data quality from the trusted experts in genomics.

    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    disaster recovery
    How Safe Are Your Samples?

    Plastic storage tubes are used in laboratories worldwide to store biological and chemical samples.

    Product Support Plans
    Product Support Plans

    Azenta  Life Sciences' world class service team is committed to ensuring you meet your business objectives by providing a flexible portfolio of service products designed to optimize up-time and productivity.

    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    Putting a Sample Kit in an envelope
    Quality Assurance Certifications

    Azenta Life Sciences has established, documented, implemented and currently maintains a quality management system that fulfills the needs of customers.

    About Azenta Life Sciences
    About Azenta Life Sciences

    We are Azenta Life Sciences. We provide unrivaled sample exploration and management solutions to help our customers accelerate discovery, development and delivery.

    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

News

Brooks Announces Intention to Separate Into Two Independent Publicly Traded Companies

May 11, 2021
Press Releases
Brooks Announces Intention to Separate Into Two Independent Publicly Traded Companies

Separation Will Create Focused, High-Growth Life Sciences and Automation Companies

Tax-Efficient Separation Expected to be Completed by End of Calendar Year 2021

 

CHELMSFORD, Mass., May 10, 2021 – Brooks Automation, Inc. (“Brooks”) (Nasdaq: BRKS) today announced its intention to separate its business into two independent, and publicly traded companies.

The transaction is intended to be structured as a pro-rata distribution of shares to Brooks shareholders in a tax-efficient manner and will establish:

  • A pure-play life sciences company with market-leading sample-based solutions and genomics services. The company will be renamed before the separation is completed to reflect its strategic focus. This business generated revenue of $449 million in the twelve months ending March 31, 2021.
  • A highly innovative automation technology company with significant expertise in semiconductor manufacturing solutions and meaningful white space to expand into multimarket automation. The company will retain the Brooks Automation name, a testament to the legacy it has built over the years. This business generated revenue of $553 million for the last twelve months ending March 31, 2021.

“This is an exciting day for Brooks and represents a critical milestone in our long-term strategy for the company. Over the past decade, we have successfully built two strong businesses in life sciences and automation,” said Steve Schwartz, President and CEO of Brooks. “We are convinced the separation will better position each of them to extend their advantages in the markets they serve.”

“Today’s announcement is the result of a thorough strategic review conducted by the Board and the management team,” said Joe Martin, Chairman of the Board of Brooks. “The creation of two independent companies, each with a distinct focus and a proven business model, is intended to drive continued momentum in both businesses and deliver shareholder value.”

Current Brooks CEO, Steve Schwartz will lead the standalone life sciences company; current Brooks CFO, Lindon Robertson, will serve as CFO. The company will be comprised of Brooks’ Life Sciences business.

Following the separation, Dave Jarzynka, current President of the Semiconductor Solutions Group business, will be named CEO of the new Brooks Automation; current Brooks Corporate Controller and Principal Accounting Officer, Dave Pietrantoni, will be named CFO. The company will be comprised of Brooks’ Semiconductor Solutions business, which includes the 2 collaborative robotics and multi-market automation business acquired on April 29, 2021.

 

Compelling Strategic Rationale for a Separation

The life sciences and semiconductor businesses operate in distinct markets, with unique business opportunities and investment requirements. The Brooks Board and management believe the separation will result in material benefits to the standalone companies, including:

  • Enhanced strategic and operational focus
  • Simplified organizational structures and improved agility
  • Distinct and clear financial profiles with compelling investment cases
  • Aligned performance incentives
  • Strong balance sheets to support organic and inorganic investments

 

Separation Details

The transaction is planned to be a pro rata distribution of shares to Brooks shareholders in a tax efficient manner. Brooks is targeting completion of the separation by the end of calendar year 2021. Completion of the separation is subject to customary market, regulatory, and other conditions. Further details on the separation will be included in future filings with the Securities and Exchange Commission. The separation will not require a shareholder vote. There can be no assurance regarding the form and timing of the separation or its completion.

Evercore is serving as financial advisor, and Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as legal advisor to Brooks.

 

Conference Call and Investor Presentation Today

The Company will host a conference call and live webcast to discuss the announcement today, in conjunction with the previously scheduled Q2 Earnings Call, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-913-8744 for domestic callers and +1-212-271- 4615 for international callers.

Analysts, investors and members of the media can access the live webcast via the Brooks website at https://brooks.investorroom.com/events. A replay will be available beginning at 8:30 a.m. ET on May 11, 2021.

 

About Brooks Automation, Inc.

Brooks (Nasdaq: BRKS) is a leading provider of life science sample-based solutions and semiconductor manufacturing solutions worldwide. With over 40 years as a partner to the semiconductor manufacturing industry, Brooks is a provider of industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world's leading semiconductor chip makers and equipment manufacturers. The Company's Life 3 Sciences business provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Brooks Life Sciences’ GENEWIZ division is a leading provider of gene sequencing and gene synthesis services. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, visit www.brooks.com.

 

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include but are not limited to statements about the ability to affect the separation of Brooks’ Life Sciences and Semiconductor Solutions Group businesses and the projected performance of the standalone companies. Factors that could cause results to differ from our expectations include the following: the impact of the COVID-19 global pandemic on the markets we serve; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q.

 

INVESTOR CONTACTS:

Sara Silverman
Director, Investor Relations
Brooks Automation
978.262.2635
sara.silverman@brooks.com

Sherry Dinsmore
Brooks Automation
978.262.4301
sherry.dinsmore@brooks.com
 

 

SOURCE Brooks Automation

Home
Facebook twitter youtube linkedin
Copyright © 2023 Azenta US, Inc.

Footer menu

  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • Terms of Use
  • Careers
  • Subscribe